

ERRATUM

Open Access



Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

Silvia Boero¹, Anna Morabito², Barbara Banelli², Barbara Cardinali³, Beatrice Dozin⁴, Gianluigi Lunardi⁵, Patrizia Piccioli⁶, Sonia Lastraioli⁷, Roberta Carosio², Sandra Salvi⁸, Alessia Levaggi³, Francesca Poggio⁹, Alessia D'Alonzo³, Massimo Romani², Lucia Del Mastro³, Alessandro Poggi¹ and Maria Pia Pistillo^{2*}

Erratum to: *J Transl Med* (2015) 13:324 DOI 10.1186/s12967-015-0680-0

It has come to the publisher's attention that the original version of this article [1] unfortunately contained an error. In Table 3, first column, the FcγRIIA 131 H>R genotypes were incorrectly labelled. In particular, V/V should have

read H/H, V/F should have read H/R and F/F should have read R/R. Please note that this correction does not change the genotype numerical values of FcγRIIA polymorphism. The correct Table 3 has been published as Table 1 in this Erratum.

Table 1 Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls

Genotypes	n (%)			P*	Alleles	n (frequency)			P°
	NEO (n = 15)	MTS (n = 10)	CTR (n = 33)			NEO (2n = 30)	MTS (2n = 20)	CTR (2n = 66)	
FcγRIIIA 158V>F				0.741	FcγRIIIA 158V>F				0.934
V/V	4 (26.7)	3 (30.0)	6 (18.2)		V	13 (0.43)	8 (0.40)	26 (0.39)	
V/F	5 (33.3)	2 (20.0)	14 (42.4)		F	17 (0.57)	12 (0.60)	40 (0.60)	
F/F	6 (40.0)	5 (50.0)	13 (39.4)						
HWE									
	P = 0.213	P = 0.065	P = 0.522						
FcγRIIA 131H>R				0.499	FcγRIIA 131H>R				0.843
H/H	3 (20.0)	4 (40.0)	9 (27.3)		H	14 (0.47)	10 (0.50)	35 (0.53)	
H/R	8 (53.3)	2 (20.0)	17 (51.5)		R	16 (0.53)	10 (0.50)	31 (0.47)	
R/R	4 (26.7)	4 (40.0)	7 (21.2)						
HWE									
	P = 0.782	P = 0.058	P = 0.845						

Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)]

Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson's χ^2 test (P* value) and the Fisher's test (P° value), respectively. Statistical significance: P < 0.05

NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy-Weinberg equilibrium. HWE was tested by the Pearson's χ^2 test (P < 0.05 indicates lack of HWE)

*Correspondence: mariapia.pistillo@hsanmartino.it

² Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST, Genoa, Italy
Full list of author information is available at the end of the article

Author details

¹ Unit of Molecular Oncology and Angiogenesis, IRCCS AOU San Martino-IST, Genoa, Italy. ² Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST, Genoa, Italy. ³ Development of Innovative Therapies Unit, IRCCS AOU San Martino-IST, Genoa, Italy. ⁴ Clinical Epidemiology Unit, IRCCS AOU San Martino-IST, Genoa, Italy. ⁵ Medical Oncology Unit, Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy. ⁶ Cellular Biology Unit, IRCCS AOU San Martino-IST, Genoa, Italy. ⁷ Laboratory of Molecular Diagnostics, IRCCS AOU San Martino-IST, Genoa, Italy. ⁸ Unit of Pathology, IRCCS AOU San Martino-IST, Genoa, Italy. ⁹ Unit of Medical Oncology 2, IRCCS AOU San Martino-IST, Genoa, Italy.

The online version of the original article can be found under doi:[10.1186/s12967-015-0680-0](https://doi.org/10.1186/s12967-015-0680-0).

Published online: 22 January 2016

Reference

1. Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D'Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Analysis of in vitro ADCC and clinical response to trastuzumab; possible relevance of FcγRIIIA/FcγRIIA genepoly-morphisms and HER-2 expression level on breast cancer cell lines. *J Transl Med*. 2015;13:324.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

